Natural Killer Cells Therapeutics Market Size, Share, and Trends 2026 to 2035

Natural Killer Cells Therapeutics Market Size and Forecast 2026 to 2035

The global natural killer cells therapeutics market size is calculated at USD 4.08 billion in 2025, grow to USD 4.57 billion in 2026, and is projected to reach around USD 12.35 billion by 2035, growing at a CAGR of 11.71% from 2026 to 2035. The market is expanding due to rising cancer prevalence and growing interest in targeted immunotherapies. Advancements in NK cell engineering and clinical trials are further accelerating market adoption.

Natural Killer Cells Therapeutics Market Key Takeaways

• North America dominated the natural killer cells therapeutics market revenue shares in 2025.
• Asia Pacific is expected to grow at the fastest CAGR in the market during the forecast period.
• By therapeutics, the NK cell therapies segment held the largest market share in 2025.
• By therapeutics, the NK cell directed antibodies segment is expected to grow at the fastest CAGR in the market during the forecast period.
• By application, the cancer segment dominated the market with a revenue share in 2025.
• By application, the gastrointestinal segment is expected to grow at the fastest CAGR in the market during the forecast period.
• By end user, the hospitals segment led the market with the largest revenue share in 2025.
• By end user, the research centers & institutes segment is expected to grow at the fastest CAGR in the market during the forecast period.

Which Factors are Driving the Growth of the Natural Killer Cells Therapeutics Market?

Natural killer cell therapeutic care is a type of immunotherapy that harnesses the body’s NK cells, innate immune lymphocytes capable of recognizing and killing tumor or virus infected cells through methods like cell expansion, genetic modification, or activation to enhance their effectiveness in treating diseases. The growth of the natural killer cell therapeutic market is driven by increasing cancer incidence, rising demand for advanced and targeted immunotherapies, and growing research investments in NK cell-based treatments. Technological advancements in cell engineering, genetic modification, and manufacturing are improving, and manufacturing are improving therapeutic efficacy and accessibility. Additionally, expanding clinical trials, favorable regulatory support, and the potential of NK cells to treat various cancers and viral infections are further fueling market expansion globally.

• For Instance, In May 2025, Coeptis Therapeutics Holdings, Inc., a biopharma firm focused on cell therapies for autoimmune disorders, cancer, and infectious diseases, launched SNAP-CAR NK cells designed to target multiple antigens.

What are the Key trends in the Natural Killer Cells Therapeutics Market in 2025?

• In April 2025, Ingenium Therapeutics secured FDA Orphan Drug Designation for its next-generation NK cell therapy aimed at treating acute myeloid leukemia (AML).
• In January 2025, Indapta Therapeutics, Inc., a biotech firm developing IDP-023 NK cell therapy for cancer, began dosing the first patients in its Phase 1 trial for multiple myeloma and non-Hodgkin’s lymphoma.

What Impact does AI have on the Natural Killer Cells Therapeutics Market?

AI is accelerating the market by enabling faster drug discovery, optimizing NK cell engineering, and improving target antigen identification. It supports predictive modeling for treatment outcomes and streamlines clinical trial design, reducing development time and costs. Additionally, AI-driven data analysis enhances personalization of NK cell therapies, boosting their efficacy and expanding potential applications in cancer and infectious disease treatments.

Report Scope of Natural Killer Cells Therapeutics Market

Market Dynamics

Driver

Advancements in NK Cell Engineering

Advancements in NK cell engineering act as a market driver because they help overcome challenges like limited lifespan, low in vivo persistence, and insufficient tumor infiltration of NK cells. Innovative approaches improve cell survival, enhance immune response modulation, and enable combination with other therapies for synergistic effects. These improvements expand the therapeutic potential across diverse cancers and diseases, making NK cell therapies more effective, commercially viable, and appealing to healthcare providers and investors.

• For Instance, In January 2025, researchers at The University of Texas MD Anderson Cancer Center reported interim results from a Phase I/II trial using cord blood–derived CD19-targeted CAR NK cell therapy in patients with relapsed or refractory B-cell malignancies. The study achieved an overall response rate of 48.6% at 100 days, with one-year progression-free survival of 32% and overall survival of 68%, all while exhibiting an excellent safety profile no severe cytokine release syndrome, neurotoxicity, or graft-versus-host disease were observed.
  Restraint

High Manufacturing and Production Costs

High manufacturing and production costs hinder the NK cell therapeutic market as they lead to higher pricing for end treatments, reducing patient affordability and healthcare systems adoption. Limited reimbursement coverage in many countries exacerbates the challenge, making it difficult for hospitals to integrate these therapies. The high upfront investment required from biotech firms also discourages smaller players from entering the market, slowing innovation and limiting competitive pricing that could drive wider accessibility.

Opportunity

Expansion into Solid Tumor Treatments

Targeting solid tumors offers a significant growth avenue for the NK cell therapeutics market because these cancers account for the majority of global cancer cases. Overcoming challenges like immune evasion and poor NK cell penetration into dense tumor tissues could unlock vast patient populations. Breakthroughs in bispecific engagers, nanocarrier delivery, and oncolytic virus combination are paving the way for NK cell use in solid tumors, potentially transforming treatment landscapes and creating substantial commercial potential.

• For Instance, In May 2025, NKGen Biotech presented interim results from a Phase I trial of SNK02, a cryopreserved allogeneic NK cell therapy, at the ASCO Annual Meeting. Administered without lymphodepletion in patients with advanced, treatment-refractory solid tumors, SNK02 demonstrated a 100% rate of stable disease among those completing eight treatment cycles and was well tolerated as monotherapy, underscoring its potential to expand NK cell use into challenging solid tumor settings.

Segmental Insights

How did the NK cell Therapies Dominate the Market in 2025?

In 2025, the NK cell therapy segment led the natural killer cells therapeutics market largely due to a surge in successful early and late-stage clinical trials, which strengthened physician confidence and patients' demand. Partnerships between biotech firms and academic institutions accelerated innovation, which improved manufacturing scalability from a growing supply constraints. Moreover, the segment benefited from a growing pipeline of therapies for both hematologic and solid tumors, expanding its treatment scope and reinforcing its dominant market share.

The NK cell directed antibodies segment is set to witness the fastest CAGR, as ongoing research is uncovering novel tumor-specific antigens that improve targeting efficacy. Growing success in integrating these antibodies with existing treatment regimens is boosting adoption, while their lower risk of severe immune-related side effects compared to some cell therapies is increasing clinicians performance. Expanding clinical trials across multiple cancer types and favorable early efficacy data are further accelerating their development and future market uptake.

What made the Cancer Segment Dominant in the Market in 2025?

The cancer segment led the natural killer cells therapeutics market in revenue share as rising patient awareness and physician acceptance boosted adoption rates. Strong collaborations between biotech firms and cancer research centers accelerated the introduction of innovative NK-based therapies. Moreover, reimbursement initiatives in key markets and integration of NK cell treatments into combination regimens with chemotherapy or checkpoint inhibitors enhanced clinical outcomes, making cancer the primary and most commercially viable application areas for NK cell therapeutics.

The gastrointestinal segment is projected to record the fastest CAGR as advancements in biomarkers are enabling more precise NK cell-based targeting of GI tumors. Increasing collaborations between immunotherapy developers and gastro-oncology research centers are accelerating significant investment. Additionally, the segment benefits from growing integration of NK cell therapies into multidisciplinary treatment plans, positioning them as a promising option for improving survival rates of difficult-to-treat gastrointestinal cancers.

How did the Hospitals Segment Dominate the Market in 2025?

The hospitals segment captured the largest revenue share in 2025 as centralized procurement systems and established supply chains ensured consistent access to NK cell therapies. Their capacity to integrate novel treatment into existing oncology programs streamlined adoption, while affiliations with research institutions and facilities provided early access to breakthrough therapies. Moreover, hospitals' role in multidisciplinary care allowed seamless coordination between oncologists, immunologists, and laboratory teams, enhancing treatment outcomes and reinforcing their position as the primary end users in this market.

The research centers & institutes segment is projected to grow at the fastest CAGR due to their expanding focus on niche therapeutics areas, such as rare cancers and complex viral infections, where NK cell therapies show untapped potential. Their flexibility to explore experimental approaches without commercial constraints fosters rapid innovation. Additionally, global collaborations, data-sharing initiatives, and participation in international consortia are accelerating knowledge exchange, helping translate laboratory discoveries into viable NK cell therapeutic candidates more efficiently.

Regional Insights

How is North America Contributing to the Expansion of the Natural Killer Cells Therapeutics Market?

In 2025, North America dominated the natural killer (NK) cell therapeutics market due to its well-established healthcare infrastructure, high adoption of advanced immunotherapies, and significant investment in research and development. Strong presence of leading biotechnology and pharmaceutical companies, coupled with extensive clinical trial activities, accelerated innovation and product avahas ilability. Favorable regulatory frameworks, higher healthcare expenditure, and robust reimbursement policies further supported market growth. Additionally, rising cancer prevalence and strong collaborations between industry and academic institutions reinforced the region’s leading market position.

How is Asia-Pacific Accelerating the Market?

Asia-Pacific is projected to grow at the fastest CAGR as the region sees rapid expansion of specialized immunotherapy centers and a surge in skilled research talent focusing on NK cell innovations. Rising participation in multinational clinical trials is improving early access to breakthrough therapies. Additionally, strategic investments from global pharmaceutical companies into local manufacturing hubs are boosting supply capabilities, while increasing patient awareness and demand for next-generation cancer treatments are creating strong momentum for NK cell therapy adoption.

Top Companies in the Natural Killer Cells Therapeutics Market

• Bristol-Myers Squibb Company
• Cytovia Therapeutics
• Glycostem
• ImmunityBio, Inc.
• Biohaven Pharmaceuticals
• Fate Therapeutics
• EMERcell
• Merck KGaA
• Phio Pharmaceuticals
• Sanofi

Recent Developments in the Natural Killer Cells Therapeutics Market

• In February 2025, NKGen Biotech received FDA Fast Track designation for Truculence, an ex vivo expanded autologous NK cell therapy for moderate Alzheimer’s disease. This status allows for Accelerated Approval, Priority Review, and Rolling Review, potentially speeding its path to market. 
• In April 2025, Sanofi progressed its NK cell engager SAR443579/IPH6101 into Phase II of an ongoing Phase I/II trial (NCT05086315) for multiple blood cancers. The first patient has been dosed, and the study will assess the therapy’s safety, pharmacokinetics, pharmacodynamics, and anti-leukemic activity across various hematologic malignancies.

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2035. For this study, Nova one advisor, Inc. has segmented the Natural Killer Cells Therapeutics Market.

By Therapeutics

• NK Cell Therapies
• NK Cell Directed Antibodies

By Application

• Cancer
• Gastrointestinal Diseases
• Immunoproliferative Disorders
• Others

By End User

• Research Centers & Institutes
• Hospitals
• Others

By Regional

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa (MEA)